News and Announcements
Kazia Therapeutics shares a video interview with leading cancer researcher Dr Matt Dun
- Published June 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia Therapeutics releases a video interview with leading cancer researcher at the Hunter Medical Research Institute and The University of Newcastle, Dr Matt Dun.
Dr Dun kindly shared some of his time recently to discuss Diffuse Intrinsic Pontine Glioma (DIPG) – the most aggressive form of childhood brain cancer.
DIPG is a deadly disease, with a survival rate of less than 1%, and most commonly affects children between four and 11 years old.
Dr Dun’s research is particularly focused on predicting the progression of DIPG in its early stages and testing new therapies in a bid to improve survival.
Kazia’s brain cancer drug GDC-0084 is one of the therapies he has been working with.
In the video, Dr Dun talks about:
- The incidence of DIPG, with around 15-20 kids diagnosed with the disease each year in Australia and around 300 children in the US
- His very personal motivations to find new treatments for this devastating disease
- His focus on a cancer pathway called PI3 kinase
- How GDC-0084 is one of the most potent PI3 kinase inhibitors and has the potential to cross the blood brain barrier – a very important aspect in treating brain cancer
Watch the video here
Dr Dun’s story was also featured in The Daily Telegraph on the weekend.
About Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
